Promethera strengthens NASH therapeutic pipeline with acquisition

New report reveals trends and priorities for life science industry
Credit: science photo

Promethera Biosciences has acquired Baliopharm AG, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer.

Promethera said the deal complements its pipeline with an innovative antibody-based drug candidate that specifically binds to the tumour necrosis factor receptor 1 (TNF-R1).

Combining this novel therapeutic strategy with Promethera’s unique liver cell-based therapies could provide improved treatment option for patients suffering from Nonalcoholic steatohepatitis (NASH) and potentially other severe liver diseases.

With the TNF-alpha pathway and its Receptor 1 (R1) being implicated in the progression of many inflammatory diseases, including chronic liver diseases leading to fibrosis, a therapeutic antibody approach is a valuable strategy in its own right as well as in combination with Promethera’s cell-based medicines such as the HepaStem technology.

Through the transaction, Promethera gains control over Baliopharm’s entire antibody development programs in particular the one focused on establishing a unique next-generation and selective TNF-R1 inhibitor including the novel, antibody based monovalent drug candidate Atrosimab.